Announce the top 10 gross profit margin of listed pharmaceutical companies: 9 over 90% of these products are the most profitable

In 2018, national institutional reform, anti-cancer drug "zero tariff", medical insurance fee control, 4 + 7 volume procurement and other policies were implemented to accelerate the restructuring of the industry pattern Before half of 2019, several listed pharmaceutical companies were inquired by the Shanghai Stock Exchange and 77 pharmaceutical companies were audited by the Ministry of finance At one time, "sales expenses" was put on the hot topic list It can be said that the chain reaction caused by a number of major initiatives makes everyone in the pharmaceutical industry unable to stay out of the business Next, take a look at the top 10 enterprises with sales gross margin in 2018 and their products with explosive potential By the end of May, more than 200 listed pharmaceutical companies had released their 2018 report cards Among them, according to the gross profit rate (gross profit rate) disclosed by various enterprises, the gross profit rate of 9 pharmaceutical enterprises has reached more than 90%, and that of 33 enterprises has reached more than 80% Then, by industry (biological medicine, chemical medicine and traditional Chinese Medicine), which enterprises are listed in the top 10 of gross profit margin in 2018? 1 Layout of core products to help biopharmaceutical enterprises achieve "Grand Slam" in the field of biopharmaceutical products According to the annual report, the sales gross profit rate of the top 10 enterprises in 2018 has its own advantages and disadvantages, such as the innovative drug "suling" of Kangchen pharmaceutical, the "dust mite drops" of Wuhan bio, and the healthy "alo" of Dezhan Let's take a look at the important products that drive the enterprise's profits: gold products strongly drive the enterprise's revenue: Kangchen and Huawei ranked first and second among the top 10 enterprises in terms of sales gross profit rate in 2018, with their gold products, Kangchen pharmaceutical and Huawei bio all drive the enterprise's annual revenue and gross profit rate Among them, Kangchen Pharmaceutical Co., Ltd., ranking first, achieved an operating revenue of 1.022 billion yuan in 2018, an increase of 73.08% over the same period of last year The gold single "suling" achieved a record of 970 million yuan, accounting for 94.91% of the total revenue and 95.08% of the gross profit margin of the whole year The second largest company in China, sinobio is the only one that produces standardized sublingual desensitization drugs Dust mite drops, a heavy-duty product of the company, ranks first in the dust mite desensitization drug market In 2018, 5665964 pieces were sold, with a revenue of 495 million yuan, accounting for 98.80% of the total revenue and a gross profit rate of 94.63% It can be seen that the brand products of Kangchen Pharmaceutical Co., Ltd and Huawei bio have an absolute market advantage However, if other similar products flow into the same treatment field, their market share, annual sales volume, gross profit rate, etc may encounter the risk of discount A number of mature products have made concerted efforts to promote stable growth in revenue: in addition to the above two enterprises, Kangtai, saisheng and Watson, all other enterprises hold several products, penetrate them into a disease field, and then create a series of products to maintain a steady growth in gross profit rate Kangtai biological's main business ranks the third in vaccine R & D, production and sales Its 2018 performance shows that the company's own product, class II vaccine, had a revenue of 1.905 billion in 2018, accounting for 94.47% of the total revenue and a gross margin of 93.69% The main driving force for maintaining high gross profit margin is the four listed products of hepatitis B vaccine, Hib vaccine, leprosy vaccine and vaccine Similarly, saisheng pharmaceutical ranked fourth and Watson bio ranked sixth Among them, saisheng pharmaceutical's profit-making business focuses on two major fields: cardiovascular and cerebrovascular diseases and immune diseases, while maintaining the company's gross profit rate to maintain 80% and steady growth, there are four products, namely, sodium deoxynucleotide injection (gross profit rate of 91.34%); plasmin injection (gross profit rate of 87.80%); ganoderma polysaccharide injection (gross profit rate of 83.28%); GM1 (gross profit rate of 80.89%); Watson ranked sixth Biology is an enterprise with rich vaccine product line in China According to the annual report, the revenue of Watson biological independent vaccine is 830 million, accounting for 93.92% of the total revenue, and the gross profit margin has been maintained for more than 80% for two consecutive years Its contribution mainly comes from three products with an annual sales volume of over 100 million, namely, Haemophilus influenzae combination vaccine (precharge) (gross margin of 88.94%), Haemophilus influenzae combination vaccine (Xilin) (gross margin of 89.44%) and pneumococcus polysaccharide vaccine (gross margin of 93.37%) In addition, although some businesses involve many fields, the main engine for improving overall operating revenue and gross profit margin is the sales volume of biological products "Catch fish with wide net": Changchun hi tech, Anke, Shuanglu and other high-tech businesses involve biomedicine, health industry and real estate According to the annual report, the company's genetic engineering drugs and biological drugs generated 4.222 billion yuan of revenue in 2018, accounting for 78.57% of the revenue and 92.09% of the gross profit margin Its representative products are growth hormone drugs (polyethylene glycol recombinant human growth hormone injection, recombinant human growth hormone, etc.), freeze-dried live attenuated varicella vaccine, human rabies vaccine Its main business covers biological products, peptide medicine, modern Chinese patent medicine and other industries Among them, biological products contributed 760 million yuan in 2018, accounting for 52.33% of the total revenue and 88.24% of the gross profit margin, ranking the leading position in the above industries The main businesses of Shuanglu Pharmaceutical Co., Ltd and Anke biological Co., Ltd are involved in the research, development, production and operation of genetic engineering and related drugs According to the annual report, Shuanglu pharmaceutical's biological and biochemical medicine revenue in 2018 was 1.772 billion, accounting for 81.77% of the total revenue, with a gross profit margin of 77.50% The representative products include risperidin, hingil, etc.; chemical medicine revenue accounted for relatively small, but with a gross profit margin of 89.90%, and the following new products such as lenalidomide, enoxaparin sodium and docetaxel may become the new driving force for the company's performance improvement The biological business of the Fourth Ring Road in Jiangsu Province involves many fields, such as medicine, timber forest, landscape engineering, etc., but the pharmaceutical sector dominates in terms of revenue According to the annual report, IL and EPO are the two carriages to drive the profits in the field of medicine, and the total annual revenue is nearly 300 million, accounting for 74.62% of the total revenue, and the gross profit rates are 92.96% and 76.95% respectively Tonghua Dongbao products cover biological products, Chinese patent medicine and chemical medicine But biological products stand out According to the annual report, the company's recombinant human insulin APIs and injection products generated revenue of 1.941 billion, accounting for 72.02% of the total revenue, with a gross margin of 86.72%, far higher than the gross margin of proprietary Chinese medicine (52.14%) and medical devices (30.16%) 2 Compete for the big market, chemical enterprise star variety "carry the banner" chemical industry sales gross profit rate top 10 enterprises in 2018 The gross profit margin of chemical enterprises is more than 83%, and hundred million varieties are distributed in many fields, such as anticancer, cardiovascular, anti infection, etc., such as ektinib of Beida, dexmedetomidine hydrochloride injection of Hengrui medicine, engendine of guangshengtang, etc In the field of anti-tumor: Beida pharmaceutical and Hengrui pharmaceutical, the top two pharmaceutical companies, achieved an operating revenue of 1.224 billion yuan, up 19.27% year on year As the first small molecule targeted anticancer drug with independent intellectual property rights in China, its sales volume has continued to increase since it was launched in 2018 In 2018, the number of sales boxes exceeded 1 million for the first time, and the sales amount reached a new record, i.e 1.208 billion yuan, accounting for 98.72% of the total revenue, with a gross profit rate of 95.27% In 2018, the operating revenue of Hengrui pharmaceutical, a research and development group in the field of anti-tumor, reached 17.418 billion yuan, an increase of 25.89% over the same period Among them, the revenue of anti-tumor products is 7.395 billion, and that of anesthesia products is 4.653 billion The gross profit rates of the two main businesses are 93.35% and 90.93% respectively, far higher than other businesses such as contrast agents In terms of product sales in 2018, the production and sales of apatinib mesylate tablets and tegio capsules increased rapidly Cardiovascular field: Dexian health ranks the second in Dexian health, with revenue of 3.291 billion in 2018, drug sales revenue accounting for 99.82% and gross profit margin of 92.81% And the company's operating revenue is generally based on the profits of its subsidiary, Jialin pharmaceutical, in the market of regulating / reducing blood lipid For example, alexin (10mg, 20mg) and trimetazidine hydrochloride capsules are the main sales force of Jialin pharmaceutical industry Among them, "alo", as the first domestic imitation of atorvastatin calcium, has successfully entered the first echelon of 4 + 7 belt volume procurement and achieved sales volume of 191 million boxes (calculated by 10mg) throughout the year, which is the core product of Jialin pharmaceutical industry's heavy money bet Nervous system: Kanghong Pharmaceutical Co., Ltd and Harbin Sanlian Pharmaceutical Co., Ltd., ranking the third, achieved an operating revenue of 2.917 billion yuan in 2018, an increase of 4.70% year on year The products on the market include Ophthalmology, brain, digestive and other clinical fields According to the annual report, the drug revenue consists of proprietary Chinese medicine, chemical medicine and biological products, accounting for 29.59%, 40.11% and 30.24% of the total revenue respectively Among them, those with a gross profit rate of more than 90% are chemicals and biological products The most representative chemical products are aripiprazole orally disintegrating tablets and biological products are conbercept ophthalmic injection In addition, in the field of nervous system occupies a place there is the eighth Harbin Sanlian In 2018, the company achieved an operating revenue of 2.173 billion yuan, an increase of 89.11% over the same period last year Its products cover many fields of treatment, such as nervous system, cardiovascular and cerebrovascular system, systemic anti infection, etc., but the core competitive varieties are concentrated in nervous system, such as olacetam injection and mirtazapine tablet It is worth mentioning that, for example, according to the classification of dosage forms (freeze-dried powder injection, small volume injection, large infusion), the gross profit rate of Harbin Sanlian freeze-dried powder injection and small volume injection exceeds 90%, among which the operating revenue of freeze-dried powder injection in 2018 is nearly 1 billion Anti infection: Lingkang Pharmaceutical Co., Ltd., Haichen Pharmaceutical Co., Ltd and Puli Pharmaceutical Co., Ltd., ranking fourth, achieved an operating revenue of 1.67billion yuan in 2018, an increase of 66.10% year on year Its main products include parenteral nutrition medicine, anti infective medicine and digestive system medicine, and the anti infective field has a gross profit margin of more than 90%, that is 94.79% Haichen pharmaceutical, ranked sixth, achieved a total operating revenue of 712 million yuan in 2018, an increase of 56.45% year on year The core products focus on diuretics, antibiotics, digestion, antiviral and other fields The total revenue of antibiotics (190 million), diuretics (293 million) and digestive products (86 million) accounted for 79.97% of the total revenue, and the gross profit margin was 84.16%, 93.13% and 86.63% respectively Puli pharmaceutical, ranked ninth, achieved revenue of 624 million yuan in 2018, an increase of 92.07% year on year Among them, the revenue of antiallergic drugs and antibiotics are over 100 million, accounting for nearly 70% of the total operating revenue, and their gross profit margins are 89.92% and 79.82% respectively The non steroidal anti-inflammatory drugs accounted for 10.55% of the total revenue and 87.97% of the gross profit margin Digestive system: Hanyu pharmaceutical industry, ranking seventh in Hanyu pharmaceutical industry, achieved an operating revenue of 1.264 billion yuan in 2018, an increase of 1.46% year on year Its main distribution area is chronic disease treatment products dominated by metabolic treatment drugs, and its main preparation products are peptide injection According to the annual report, the products with high revenue contribution rate in 2018 are thymopentin for injection (147 million), somatostatin for injection (239 million) and terlipressin for injection (194 million), with gross profit rates of 83.68%, 79.22% and 96.70% respectively Liver disease: the business income of guangshengtang, the 10th largest in guangshengtang, was 402 million yuan, an increase of 35.89% year on year Its four major anti HBV products (agandine, he Ganding, en Ganding and fuganding) achieved a sales revenue of 331 million yuan, accounting for 82.30% of the total revenue, and the gross profit rate is the highest of all kinds of products, namely 86.40% 3 To help traditional Chinese medicine enterprises "resist pressure", the core and exclusive varieties become the top 10 enterprises of gross profit margin in 2018 in the field of "dinghaishen needle" traditional Chinese medicine preparation The sales volume of core products of traditional Chinese medicine enterprises suffered impact due to the influence of policies such as medical insurance payment cost control, national basic drug catalog, auxiliary drug catalog and "two ticket system" However, the gross profit of the above-mentioned enterprises basically remains above 80%, and their patents and exclusive varieties are indispensable Next, according to the above enterprise core varieties, the dosage forms are classified as injection type and mouth type